Abstract
A large body of evidence on brain development and ageing has revealed that inflammatory processes profoundly affect brain functions during life span of mammalians, including humans. Activation of innate immune mechanisms leading to pro-inflammatory cytokine up-regulation is involved in devastating and disabling human brain illnesses, as Alzheimers disease (AD), a progressive neurodegenerative disease that causes dementia in the elderly. Emerging data indicate that the cytokine Interleukin (IL)-18, one of the key mediator of inflammation and immune response, has relevance in the physiopathological processes of the brain, by ultimately influencing the integrity of neurons and putatively contributing to AD. In this review, the relationship between specific IL-18-mediated processes and AD neurodegeneration is summarized and clinical studies pointing to a role of the cytokine in the pathology are discussed. Altogether, the presented data indicate that a more complete knowledge of the molecular mechanisms underlying IL-18 implication in neuroinflammatory and neurodegenerative pathways could contribute toward the development of new therapeutic strategies for AD.
Keywords: Interleukin-18, Alzheimer's disease, neuroinflammation, cytokines
Current Pharmaceutical Design
Title: Interleukin-18, From Neuroinflammation to Alzheimers Disease
Volume: 16 Issue: 38
Author(s): Paola Bossu, Antonio Ciaramella, Francesca Salani, Diego Vanni, Ilaria Palladino, Carlo Caltagirone and Giuseppe Scapigliati
Affiliation:
Keywords: Interleukin-18, Alzheimer's disease, neuroinflammation, cytokines
Abstract: A large body of evidence on brain development and ageing has revealed that inflammatory processes profoundly affect brain functions during life span of mammalians, including humans. Activation of innate immune mechanisms leading to pro-inflammatory cytokine up-regulation is involved in devastating and disabling human brain illnesses, as Alzheimers disease (AD), a progressive neurodegenerative disease that causes dementia in the elderly. Emerging data indicate that the cytokine Interleukin (IL)-18, one of the key mediator of inflammation and immune response, has relevance in the physiopathological processes of the brain, by ultimately influencing the integrity of neurons and putatively contributing to AD. In this review, the relationship between specific IL-18-mediated processes and AD neurodegeneration is summarized and clinical studies pointing to a role of the cytokine in the pathology are discussed. Altogether, the presented data indicate that a more complete knowledge of the molecular mechanisms underlying IL-18 implication in neuroinflammatory and neurodegenerative pathways could contribute toward the development of new therapeutic strategies for AD.
Export Options
About this article
Cite this article as:
Bossu Paola, Ciaramella Antonio, Salani Francesca, Vanni Diego, Palladino Ilaria, Caltagirone Carlo and Scapigliati Giuseppe, Interleukin-18, From Neuroinflammation to Alzheimers Disease, Current Pharmaceutical Design 2010; 16 (38) . https://dx.doi.org/10.2174/138161210794519147
DOI https://dx.doi.org/10.2174/138161210794519147 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets The Nuclear Molecular Imaging of Protein Brain Receptors in Chronic Pain
Current Protein & Peptide Science The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Anticancer Agents: VTA or VDA
Current Bioactive Compounds Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology Cytoskeletal Pathologies of Age-Related Diseases between Elderly Sri Lankan (Colombo) and Indian (Bangalore) Brain Samples
Current Alzheimer Research Association Studies of Sporadic Parkinson’s Disease in the Genomic Era
Current Genomics Prognostic Significance of Homocysteine Levels in Acute Ischemic Stroke: A Prospective Cohort Study
Current Neurovascular Research Motif Discovery in Speech: Application to Monitoring Alzheimer’s Disease
Current Alzheimer Research New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology Cholesterol in Alzheimers Disease: Unresolved Questions
Current Alzheimer Research Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Inflammatory Drugs in the Treatment of Neurodegenerative Diseases: Current State
Current Pharmaceutical Design Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease
Current Alzheimer Research Role of Nicotinic and Muscarinic Receptors on Synaptic Plasticity and Neurological Diseases
Current Pharmaceutical Design Vitamin D: A Regulator of Metabolism and Inflammation
Current Nutrition & Food Science Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research